Work

Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.1087

Authors: Karen A. Gelmon, Peter A. Fasching, Fergus Couch, Judith Balmana Gelpi, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Sabine Ano, Joyce O'Shaughnessy

Institutions: BC Cancer Agency, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Mayo Clinic, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Gustave Roussy, Fondation Gustave Roussy, University Hospital of Geneva, AstraZeneca (United Kingdom), Baylor University Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031628952

Cites:

Cited by: 3

Related to: 10